Once-weekly semaglutide versus placebo for the treatment of type 2 diabetes and chronic kidney disease in Denmark: A long-term cost-effectiveness analysis based on FLOW
Authors' conclusion
Adding semaglutide to SoC was projected to be highly cost-effective over the long term in people with T2D and CKD in a Danish healthcare setting, based on patient characteristics and treatment effects from FLOW.
Study context
- Population
- People with T2D and chronic kidney disease (CKD) in Denmark; baseline cohort characteristics from FLOWmodelled cohort
- Comparison
- Once-weekly semaglutide 1 mg vs placebo, both added to standard of care
- Outcome
- Quality-adjusted life expectancy and costs, full population
- Follow-up
- Lifetime
Methodological detailslifetime time horizon, Danish healthcare setting, costs in 2023 DKK, subgroups by SGLT2i use at baseline
- Lifetime time horizon
- Danish healthcare setting
- Costs in 2023 DKK
- Subgroups by SGLT2i use at baseline
Main finding
As reported in the abstract
lifetime
QALY gain
0.60 QALYs
higher with semaglutide
Per-person cost savings
6,068 DKK
lower costs with semaglutide
Further findings
| Outcome | Estimate |
|---|---|
| Subgroup receiving SGLT2i at baseline · lifetimeSemaglutide vs Placebo · higher with semaglutide | QALY gain 0.44 QALYs |
| Subgroup receiving SGLT2i at baseline · lifetimeSemaglutide vs Placebo | ICER 19,167 DKK per QALY gained |
| Subgroup not receiving SGLT2i at baseline · lifetimeSemaglutide vs Placebo · higher with semaglutide | QALY gain 0.62 QALYs |
| Subgroup not receiving SGLT2i at baseline · lifetimeSemaglutide vs Placebo · lower costs with semaglutide | per-person cost savings 9,212 DKK |
Subgroup receiving SGLT2i at baseline · lifetime
- Semaglutide cost-effective
Subgroup not receiving SGLT2i at baseline · lifetime
- Semaglutide dominant vs placebo
Original publication
Once-weekly semaglutide versus placebo for the treatment of type 2 diabetes and chronic kidney disease in Denmark: A long-term cost-effectiveness analysis based on FLOW. Cardiovasc Diabetol. Published 20 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →